Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma

Nicholas W. Hamel, Thomas J. Sebo, Timothy O. Wilson, Gary Keeney, Patrick C. Roche, Vera Jean Suman, Theresa C. Hu, Karl C. Podratz

Research output: Contribution to journalArticle

58 Citations (Scopus)

Abstract

The degree of expression of p53 and proliferating cell nuclear antigen (PCNA) was measured in archival samples from 221 patients managed surgically for endometrial carcinoma between 1979 and 1983. With use of primary antibodies to the p53 protein (DO7) and PCNA (PC10), immunoperoxidase nuclear staining of paraffin-embedded tissue was performed. The computerized CAS200 Image Analysis System was used to determine the percentage of nuclear area stained. There was no evidence to conclude that progression-free survival differed with respect to PCNA expression. In contrast, intense p53 expression (66% or more nuclear area stained) was significantly associated with compromised progression-free survival both in the analysis of all stages (P < 0.001) and in the subset of patients with stage I disease (P < 0.001). Intense expression of p53 was significantly associated with other prognostic indicators, including stage, grade, depth of myometrial invasion, histologic subtype, cytologic findings, DNA ploidy, and HER-2/neu expression. Multivariate analysis identified four independent prognostic factors for progression-free survival in endometrial carcinoma: intense p53 expression, histologic subtype, DNA ploidy status, and HER-2/neu expression. When none of these four independent factors are present, the 4-year progression-free survival is 96%. In contrast, it is 63% when one or more of these factors are present (P < 0.001) and 40% when two or more factors are present (P < 0.001).

Original languageEnglish (US)
Pages (from-to)192-198
Number of pages7
JournalGynecologic Oncology
Volume62
Issue number2
DOIs
StatePublished - Aug 1996

Fingerprint

Proliferating Cell Nuclear Antigen
Endometrial Neoplasms
Disease-Free Survival
Ploidies
DNA
Paraffin
Multivariate Analysis
Staining and Labeling
Antibodies
Proteins

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Oncology

Cite this

Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. / Hamel, Nicholas W.; Sebo, Thomas J.; Wilson, Timothy O.; Keeney, Gary; Roche, Patrick C.; Suman, Vera Jean; Hu, Theresa C.; Podratz, Karl C.

In: Gynecologic Oncology, Vol. 62, No. 2, 08.1996, p. 192-198.

Research output: Contribution to journalArticle

Hamel, Nicholas W. ; Sebo, Thomas J. ; Wilson, Timothy O. ; Keeney, Gary ; Roche, Patrick C. ; Suman, Vera Jean ; Hu, Theresa C. ; Podratz, Karl C. / Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. In: Gynecologic Oncology. 1996 ; Vol. 62, No. 2. pp. 192-198.
@article{08faf149759c457e8c4d7de585f1e9cf,
title = "Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma",
abstract = "The degree of expression of p53 and proliferating cell nuclear antigen (PCNA) was measured in archival samples from 221 patients managed surgically for endometrial carcinoma between 1979 and 1983. With use of primary antibodies to the p53 protein (DO7) and PCNA (PC10), immunoperoxidase nuclear staining of paraffin-embedded tissue was performed. The computerized CAS200 Image Analysis System was used to determine the percentage of nuclear area stained. There was no evidence to conclude that progression-free survival differed with respect to PCNA expression. In contrast, intense p53 expression (66{\%} or more nuclear area stained) was significantly associated with compromised progression-free survival both in the analysis of all stages (P < 0.001) and in the subset of patients with stage I disease (P < 0.001). Intense expression of p53 was significantly associated with other prognostic indicators, including stage, grade, depth of myometrial invasion, histologic subtype, cytologic findings, DNA ploidy, and HER-2/neu expression. Multivariate analysis identified four independent prognostic factors for progression-free survival in endometrial carcinoma: intense p53 expression, histologic subtype, DNA ploidy status, and HER-2/neu expression. When none of these four independent factors are present, the 4-year progression-free survival is 96{\%}. In contrast, it is 63{\%} when one or more of these factors are present (P < 0.001) and 40{\%} when two or more factors are present (P < 0.001).",
author = "Hamel, {Nicholas W.} and Sebo, {Thomas J.} and Wilson, {Timothy O.} and Gary Keeney and Roche, {Patrick C.} and Suman, {Vera Jean} and Hu, {Theresa C.} and Podratz, {Karl C.}",
year = "1996",
month = "8",
doi = "10.1006/gyno.1996.0214",
language = "English (US)",
volume = "62",
pages = "192--198",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma

AU - Hamel, Nicholas W.

AU - Sebo, Thomas J.

AU - Wilson, Timothy O.

AU - Keeney, Gary

AU - Roche, Patrick C.

AU - Suman, Vera Jean

AU - Hu, Theresa C.

AU - Podratz, Karl C.

PY - 1996/8

Y1 - 1996/8

N2 - The degree of expression of p53 and proliferating cell nuclear antigen (PCNA) was measured in archival samples from 221 patients managed surgically for endometrial carcinoma between 1979 and 1983. With use of primary antibodies to the p53 protein (DO7) and PCNA (PC10), immunoperoxidase nuclear staining of paraffin-embedded tissue was performed. The computerized CAS200 Image Analysis System was used to determine the percentage of nuclear area stained. There was no evidence to conclude that progression-free survival differed with respect to PCNA expression. In contrast, intense p53 expression (66% or more nuclear area stained) was significantly associated with compromised progression-free survival both in the analysis of all stages (P < 0.001) and in the subset of patients with stage I disease (P < 0.001). Intense expression of p53 was significantly associated with other prognostic indicators, including stage, grade, depth of myometrial invasion, histologic subtype, cytologic findings, DNA ploidy, and HER-2/neu expression. Multivariate analysis identified four independent prognostic factors for progression-free survival in endometrial carcinoma: intense p53 expression, histologic subtype, DNA ploidy status, and HER-2/neu expression. When none of these four independent factors are present, the 4-year progression-free survival is 96%. In contrast, it is 63% when one or more of these factors are present (P < 0.001) and 40% when two or more factors are present (P < 0.001).

AB - The degree of expression of p53 and proliferating cell nuclear antigen (PCNA) was measured in archival samples from 221 patients managed surgically for endometrial carcinoma between 1979 and 1983. With use of primary antibodies to the p53 protein (DO7) and PCNA (PC10), immunoperoxidase nuclear staining of paraffin-embedded tissue was performed. The computerized CAS200 Image Analysis System was used to determine the percentage of nuclear area stained. There was no evidence to conclude that progression-free survival differed with respect to PCNA expression. In contrast, intense p53 expression (66% or more nuclear area stained) was significantly associated with compromised progression-free survival both in the analysis of all stages (P < 0.001) and in the subset of patients with stage I disease (P < 0.001). Intense expression of p53 was significantly associated with other prognostic indicators, including stage, grade, depth of myometrial invasion, histologic subtype, cytologic findings, DNA ploidy, and HER-2/neu expression. Multivariate analysis identified four independent prognostic factors for progression-free survival in endometrial carcinoma: intense p53 expression, histologic subtype, DNA ploidy status, and HER-2/neu expression. When none of these four independent factors are present, the 4-year progression-free survival is 96%. In contrast, it is 63% when one or more of these factors are present (P < 0.001) and 40% when two or more factors are present (P < 0.001).

UR - http://www.scopus.com/inward/record.url?scp=0030220134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030220134&partnerID=8YFLogxK

U2 - 10.1006/gyno.1996.0214

DO - 10.1006/gyno.1996.0214

M3 - Article

C2 - 8751548

AN - SCOPUS:0030220134

VL - 62

SP - 192

EP - 198

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -